CD19 NEX-T (BMS-986353) Next-Generation Chimeric Antigen Receptor (CAR) T Cell Therapy in Severe Refractory Autoimmune Diseases

• Leveraging extensive CAR T cell manufacturing experience to establish the nextgeneration NEX-T manufacturing process
• Assessing the pharmacokinetics and pharmacodynamics of NEX-T CAR T cell therapy in a diverse patient population
• Establishing pooled safety and preliminary efficacy of NEX-T CAR T cell therapy in severe refractory autoimmune diseases

Speakers:

Francis Kim

Director, Early Clinical Development, Hematology & Cell Therapy

Bristol Myers Squibb